ABT SEC Filings

Abbott Laboratories (ABT) has filed an 8-K report on January 21, 2026, to announce its fourth quarter and full-year 2025 financial results. The report highlights that the company's earnings release, furnished as an exhibit, will present both GAAP and non-GAAP financial measures. Investors should pay close attention to these non-GAAP figures as Abbott's management utilizes them to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, legal reserves, and intangible amortization. The company emphasizes that these non-GAAP measures are intended to offer investors greater visibility into the underlying business performance by adjusting for factors that management considers unusual or unpredictable. While these adjustments aim to facilitate better evaluation of operational trends, investors are advised to consider these non-GAAP measures alongside, and not as a substitute for, the GAAP financial measures. The filing also includes the press release and an interactive data file for enhanced analysis.

Abbott Laboratories (ABT) filed an 8-K on December 12, 2025, primarily announcing a change in its Board of Directors composition and size. The company appointed Nita Ahuja, M.D. to its Board, effective December 12, 2025. This appointment increases the total number of directors from twelve to thirteen. The amendment to the company's bylaws formalizes this increase, reflecting a strategic expansion of its governance structure. The filing also notes the amended and restated By-Laws of Abbott Laboratories, effective December 12, 2025, as an exhibit, indicating these governance changes are now officially documented.

Abbott Laboratories (ABT) has filed an 8-K to announce a temporary trading suspension, commonly known as a "blackout period," affecting its employee benefit plans. This suspension is due to significant administrative changes within the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico). These changes include the transition of recordkeepers, trustees for certain U.S. Plan funds, and custodians for certain P.R. Plan funds. Investors should note that while this impacts plan participants' ability to transact within their retirement accounts, it does not directly affect the company's ongoing business operations or its publicly traded stock in the open market. The blackout period is scheduled to commence on December 24, 2025, and is expected to conclude by the week of January 11, 2026. During this time, participants will be unable to make changes to their contributions, investments, loans, withdrawals, or distributions. The company has formally notified its directors and executive officers of these restrictions as required by Sarbanes-Oxley Act regulations.

Abbott Laboratories (ABT) announced a significant strategic move by entering into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. This acquisition, structured as a merger where Exact Sciences will become a wholly-owned subsidiary of Abbott, represents a substantial investment by Abbott into the diagnostics and cancer screening market. The transaction is subject to customary closing conditions, including shareholder approval from Exact Sciences and regulatory clearance, such as the Hart-Scott-Rodino Antitrust Improvements Act. This deal is expected to bolster Abbott's presence in precision medicine and oncology. The financial implications include a commitment of up to $20 billion in bridge loans from Morgan Stanley Senior Funding, Inc. to finance the transaction. Abbott has scheduled an investor conference call to discuss the merger, indicating its strategic importance and the company's intent to provide detailed insights into the rationale and expected benefits of this acquisition.

Abbott Laboratories reported solid financial results for the nine months ended September 30, 2025, with total net sales increasing 6.1% to $32.9 billion, or 6.4% excluding foreign exchange impacts. This growth was primarily driven by strong performance in the Medical Devices and Established Pharmaceutical Products segments, fueled by new and existing product sales. While net earnings remained flat year-over-year at $1.64 billion for the third quarter, they increased to $4.75 billion for the nine-month period, up from $4.17 billion in the prior year, demonstrating the company's ability to generate value. The company's Medical Devices segment saw robust growth, particularly in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology, with significant contributions from continuous glucose monitoring systems and new product approvals like the Volt™ PFA System and Tendyne™ TMVR system. However, the Diagnostic Products segment experienced a decline, largely due to a significant drop in COVID-19 testing-related sales and challenging market conditions in China. Investors should note the ongoing legal proceedings related to infant formula, where Abbott maintains no material loss is probable, though the ultimate outcome could be material. The company also faces significant tax-related matters with the IRS, which it intends to contest vigorously.

Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the third quarter of 2025, announced on October 15, 2025. The filing includes a press release that presents both GAAP and non-GAAP financial measures. Investors should pay close attention to the company's use of non-GAAP figures, which exclude items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, certain regulatory costs, and tax-related adjustments. Abbott's management utilizes these non-GAAP measures to offer a clearer view of ongoing operational performance by adjusting for unusual or unpredictable factors. While these measures are intended to provide greater visibility into core business results, it is crucial for investors to consider them alongside the company's GAAP-reported financials. The press release, furnished as an exhibit, will contain the specific details of these financial outcomes and the reconciliation of non-GAAP to GAAP figures.

Abbott Laboratories reported a solid increase in net sales for the second quarter and first six months of 2025, driven primarily by strong performance in its Medical Devices and Established Pharmaceutical Products segments. Total net sales grew by 7.4% in Q2 and 5.7% year-to-date, with growth largely excluding the impact of foreign exchange. The company's profitability saw an improvement, with gross profit margin increasing to 52.7% for both periods, reflecting successful margin improvement initiatives. While the Diagnostic Products segment experienced a decline, largely due to the continued decrease in COVID-19 testing sales, the growth in other segments, particularly Medical Devices with notable strength in Diabetes Care, Heart Failure, and Structural Heart, signals a healthy underlying business. Financially, Abbott maintained a strong liquidity position with $7.0 billion in cash and cash equivalents at the end of the period. The company also continued its commitment to returning value to shareholders through dividend payments and share repurchases, with a significant authorization for future buybacks. Management highlighted ongoing investments in research and development to fuel future growth and successfully managed operating expenses despite increased spending in sales and marketing. The company is also navigating potential legal and tax matters, including ongoing IRS disputes, but management expressed confidence in their ability to manage these issues without material adverse effects on the company's financial standing.

Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the second quarter of 2025, announced on July 17, 2025. The report primarily incorporates a press release that provides a non-GAAP view of the company's earnings. Investors should note that Abbott utilizes non-GAAP financial measures, which exclude items such as acquisition-related expenses, restructuring costs, fair value adjustments to contingent consideration, certain regulatory costs, prior tax benefit adjustments, and intangible amortization. The company states these measures offer greater visibility into ongoing business performance and are used internally for assessment. While the 8-K does not provide specific Q2 2025 financial figures within the report itself, it directs investors to an accompanying press release (Exhibit 99.1) for detailed results and analysis. Investors are advised to consider these non-GAAP figures alongside the company's GAAP financial measures, as the non-GAAP metrics are presented for informational purposes to aid in evaluating operational performance and should not be viewed as a substitute for GAAP-based reporting.

Abbott Laboratories (ABT) has filed a Form 8-K to report a significant executive change. Hubert L. Allen, Executive Vice President, General Counsel, and Secretary, has announced his intention to retire from the company. Mr. Allen's departure marks the end of an era for a key leadership position within Abbott, and the company will be undergoing a transition period to fill his role. While the filing itself does not provide details on a successor or the exact timeline for Mr. Allen's retirement, investors should monitor future communications from Abbott for updates on the leadership transition. The General Counsel and Secretary role is critical for corporate governance and legal oversight, making any changes in this position a point of focus for stakeholders concerned with the company's regulatory compliance and strategic direction.

Abbott Laboratories reported strong top-line growth for the first quarter of 2025, with total net sales increasing by 4.0% to $10.36 billion, or 6.8% excluding the impact of foreign exchange. This growth was primarily driven by the Medical Devices segment, which saw a significant 9.9% increase (12.6% excluding FX), fueled by robust performance in Diabetes Care, Structural Heart, and Electrophysiology. Profitability saw a notable improvement with operating earnings rising to $1.69 billion from $1.39 billion in the prior year period. Diluted Earnings Per Share (EPS) increased to $0.76, up from $0.70 in Q1 2024. While the company is navigating some segment-specific headwinds, such as declining COVID-19 testing sales impacting the Diagnostic Products segment, the overall financial performance demonstrates resilience and continued execution across key growth areas. Investors should note the ongoing legal proceedings related to infant formula, though the company maintains no material loss is probable at this time, and the significant tax items impacting the tax rate.

Abbott Laboratories (ABT) has filed an 8-K detailing the outcomes of its Annual Meeting of Shareholders held on April 25, 2025. The primary focus of this filing is the voting results on key corporate matters. Notably, all proposed directors were re-elected to the Board, with the vast majority of votes cast in favor of each nominee. Additionally, shareholders overwhelmingly ratified the appointment of Ernst & Young LLP as the company's independent auditor for the upcoming fiscal year, indicating strong confidence in the current audit process and oversight. The advisory vote on executive compensation also passed, with nearly 90% of cast votes approving the compensation of named executive officers. While this vote is non-binding, it signals shareholder satisfaction with the company's remuneration policies. The filing provides detailed breakdowns of votes for, against, abstentions, and broker non-votes for each resolution, offering transparency into shareholder sentiment.

Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2025, announcing its first-quarter 2025 financial results. The filing primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, impairment charges, certain regulatory costs, tax benefits/expenses, and intangible amortization. The company states that these non-GAAP measures are intended to provide greater visibility into ongoing business performance and are used internally by management, but investors are cautioned to consider these in conjunction with, not as a substitute for, GAAP measures.

Abbott Laboratories reported a solid financial performance for the fiscal year ending December 31, 2024, driven by robust growth across its Medical Devices, Established Pharmaceutical Products, and Nutritional Products segments. The Medical Devices segment, in particular, demonstrated strong momentum with double-digit growth in key areas such as Diabetes Care, Structural Heart, Electrophysiology, and Heart Failure, bolstered by product approvals and expanded indications. The company's recovery in its U.S. Pediatric Nutrition business following a 2022 recall has been significant, with market share gains contributing to overall segment growth. Despite a continued decline in COVID-19 testing-related sales, which is a secular trend, Abbott's core businesses showed resilience. The company's focus on innovation and strategic acquisitions, such as Bigfoot Biomedical and Cardiovascular Systems, Inc. (CSI), are strengthening its product portfolio and market position. Abbott also demonstrated a commitment to shareholder returns by increasing its quarterly dividend and continuing share repurchases. While the company faces ongoing regulatory scrutiny and potential market challenges, its diversified business model and strong product pipeline position it for sustained growth.

Abbott Laboratories (ABT) has filed an 8-K report on January 22, 2025, announcing its financial results for the fourth quarter and full year 2024. The report primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott utilizes non-GAAP financial measures to present its performance, adjusting for items such as acquisition and divestiture expenses, restructuring costs, fair value adjustments, impairment charges, regulatory costs, tax-related adjustments, and intangible amortization. The company states that these non-GAAP measures offer better insight into ongoing business performance as assessed by management, but investors are cautioned to consider them alongside GAAP measures.

Abbott Laboratories (ABT) has filed an 8-K report detailing the extension of its Change in Control Agreements with named executive officers. These agreements, originally set to expire on December 31, 2024, have been extended through December 31, 2026, following Abbott's notification to its executives on November 12, 2024. This extension is a proactive measure that provides continued stability and security for key leadership during a potentially transitional period, ensuring continuity in strategic direction and operations.

Abbott Laboratories reported solid financial results for the third quarter and first nine months of 2024, showcasing robust top-line growth driven by its Medical Devices and Established Pharmaceutical Products segments. Despite a notable decline in COVID-19 testing sales, the company achieved an overall 4.9% increase in net sales in Q3 and 3.7% for the nine-month period, with organic growth (excluding foreign exchange) at 7.4% and 6.7%, respectively. The Medical Devices segment, in particular, demonstrated strong double-digit growth in key areas like Diabetes Care, Electrophysiology, and Structural Heart, highlighting successful product launches and strategic partnerships. Profitability also saw improvement, with gross profit margins increasing year-over-year due to higher pricing and efficiency initiatives, partially offsetting foreign exchange headwinds. While research and development expenses saw a modest increase, selling, general, and administrative costs were managed effectively. The company also continues to prioritize shareholder returns through dividend payments and share repurchases, demonstrating confidence in its financial stability and future outlook. However, investors should remain aware of ongoing legal proceedings, particularly the significant jury verdict in an infant formula lawsuit, although Abbott plans to appeal and does not currently believe a material loss is probable. Additionally, ongoing tax examinations by the IRS present a potential area of future scrutiny.

Abbott Laboratories (ABT) has filed an 8-K report on October 16, 2024, to announce its third-quarter 2024 financial results. The report primarily references a press release issued on October 16, 2024, which details these results and includes the use of various non-GAAP financial measures. Investors should note that these non-GAAP measures are presented to offer a clearer view of ongoing business performance by excluding items such as acquisition-related expenses, restructuring costs, and fair value adjustments. While Abbott's management believes these non-GAAP metrics provide valuable insights, they are intended to supplement, not replace, GAAP-based financial measures. The filing highlights the company's emphasis on providing transparency into its operational performance beyond standard accounting practices, allowing for a better evaluation of core business trends. Investors are encouraged to review the provided press release for the specific financial figures and further details on the non-GAAP adjustments.

Abbott Laboratories reported increased net sales for the second quarter and first six months of 2024, driven primarily by growth in its Medical Devices, Nutritional Products, and Established Pharmaceutical Products segments. This growth was achieved despite a significant decline in COVID-19 testing sales and unfavorable foreign exchange impacts due to a stronger U.S. dollar. Despite revenue growth, net earnings decreased year-over-year for both the quarter and the first six months, impacted by higher operating costs and expenses, including a loss on the sale of a non-core business and increased selling, general, and administrative expenses. However, operational cash flow remained strong, indicating continued business health. Investors should monitor the ongoing legal proceedings related to infant formula and the company's significant tax exposure with the IRS, which could materially impact future results.

Abbott Laboratories (ABT) has filed an 8-K report on July 18, 2024, to announce its second quarter 2024 financial results. The filing primarily incorporates a press release containing the detailed financial performance for the quarter. Investors should note that Abbott utilizes non-GAAP financial measures alongside GAAP measures to provide a clearer view of ongoing operational performance. These non-GAAP metrics exclude items such as acquisition-related expenses, restructuring costs, and amortization, which management believes offer better insight into the company's core business operations.

Abbott Laboratories reported Q1 2024 results with a modest 2.2% increase in net sales to $9.964 billion, driven by growth in Medical Devices and Established Pharmaceuticals, partially offset by a significant decline in Diagnostic Products sales. Excluding foreign exchange impacts, net sales rose 5.1%, with a notable 11.3% increase when also excluding COVID-19 testing revenue. The company's earnings before taxes stood at $1.436 billion, with Net Earnings of $1.225 billion, translating to diluted Earnings Per Share (EPS) of $0.70, a decrease from $0.75 in the prior year period. The Medical Devices segment showed strong performance, particularly in Diabetes Care (FreeStyle Libre sales up 23.3% ex-FX) and Electrophysiology, while Established Pharmaceuticals saw growth in key emerging markets. However, Diagnostic Products experienced a sharp 17.6% decline (15.5% ex-FX), primarily due to a substantial drop in COVID-19 testing sales. Operationally, gross profit margin remained stable at 50.5%, indicating effective cost management despite ongoing R&D and SG&A investments to support growth. The company continues to manage its debt prudently, with total long-term debt decreasing and maintaining strong credit ratings. Abbott also returned capital to shareholders through dividends and share repurchases. While the company faces ongoing legal and tax matters, management remains confident in their impact on the financial position. The significant decrease in COVID-19 testing revenue continues to be a headwind, but the underlying performance in key growth segments like Medical Devices provides a positive outlook.

Abbott Laboratories (ABT) announced the upcoming retirement of its Executive Vice President, Finance, Robert E. Funck, Jr., effective July 1, 2024. Mr. Funck's departure follows a distinguished 36-year career with the company. This transition marks the end of an era for a key financial executive, and investors will be keen to understand the succession plan and the impact on the company's financial leadership and strategy moving forward.

This 8-K filing from Abbott Laboratories (ABT) reports on the outcomes of its Annual Meeting of Shareholders held on April 26, 2024. The primary focus of the filing is the voting results on key corporate matters. Investors will note the overwhelming support for the re-election of the entire Board of Directors, with all nominees receiving a significant majority of the votes cast. The appointment of Ernst & Young LLP as the company's independent auditor was also overwhelmingly ratified. Finally, shareholders provided an advisory vote on the compensation of named executive officers, which passed with a strong majority, though this vote is non-binding. Overall, the results indicate continued shareholder confidence in the current leadership and governance structure of Abbott Laboratories. The robust support for the Board and auditors suggests a stable operating environment and alignment between management and its shareholders on fundamental corporate governance matters. While the executive compensation vote is advisory, the high approval rate is generally viewed as positive feedback on the company's pay practices.

Abbott Laboratories (ABT) has filed an 8-K report on April 17, 2024, to announce its first-quarter 2024 financial results. The filing primarily incorporates a press release detailing these results and highlights the use of non-GAAP financial measures. These non-GAAP measures exclude items such as acquisition-related expenses, restructuring costs, fair value adjustments, impairment charges, certain regulatory and tax items, and intangible amortization. Management utilizes these non-GAAP figures to offer investors a clearer view of ongoing operational performance, as they believe these adjustments provide better insight into the core business's results, aligning with internal performance assessments. While Abbott emphasizes the utility of these non-GAAP measures for evaluating business performance, it also strongly advises investors to consider them alongside, and not as a replacement for, standard GAAP financial metrics.

Abbott Laboratories' 2023 10-K filing highlights a challenging year marked by a significant decline in COVID-19 testing revenues, which were a substantial contributor in prior years. The company experienced an overall revenue decrease of 8.1% in 2023 compared to 2022, largely driven by a 63.3% drop in Rapid Diagnostics sales, primarily due to lower COVID-19 test demand. Despite this, Abbott demonstrated resilience across its other segments, with Medical Devices and Established Pharmaceuticals showing robust growth. The Medical Devices segment grew 14.1% (excluding foreign exchange), driven by strong performance in Diabetes Care (FreeStyle Libre), Electrophysiology, Heart Failure, and Structural Heart products. The Nutritional Products segment also saw recovery, with U.S. Pediatric Nutritionals increasing 26.6% as the company regained market share post-recall. The Established Pharmaceutical Products segment grew 10.9%, primarily in emerging markets. Investors should note the company's continued investment in R&D and strategic acquisitions to drive future growth, alongside a commitment to returning capital to shareholders through dividends and share repurchases.

Abbott Laboratories (ABT) has entered into a new Five Year Credit Agreement, establishing a $5 billion unsecured revolving credit facility. This new agreement replaces a similar facility that was set to mature in November 2025. Notably, there were no outstanding borrowings under the previous agreement at the time of its termination, and as of the filing date, there are no outstanding borrowings under the new facility. This action indicates Abbott's proactive approach to maintaining strong liquidity and financial flexibility. The new credit agreement allows for borrowings based on either a base rate or SOFR rate, with interest margins tied to Abbott's credit ratings. The company also acknowledges customary fees associated with such agreements. The termination of the old agreement and the establishment of the new one are standard financial management practices, ensuring continued access to capital for operational needs or strategic initiatives without immediate financial commitment.

Abbott Laboratories (ABT) has filed an 8-K report on January 24, 2024, announcing its fourth quarter and full-year 2023 financial results. The report primarily references a press release (Exhibit 99.1) that details these results. Investors should note that Abbott's earnings release includes both GAAP and non-GAAP financial measures. The company uses non-GAAP measures, which exclude various items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, impairment charges, and certain tax adjustments, to provide a clearer view of ongoing operational performance. While the specific financial figures are contained within the referenced press release, the 8-K filing serves as the official notification of their release and provides context for the non-GAAP adjustments made by Abbott management. Management believes these non-GAAP measures offer valuable insights into the core business performance and are used internally for performance monitoring. Investors are advised to consider these non-GAAP figures alongside GAAP measures for a comprehensive understanding of the company's financial health.

Abbott Laboratories reported a slight decrease in net sales for the third quarter of 2023, down 2.6% year-over-year to $10.143 billion. This decline was primarily driven by a significant drop in COVID-19 testing sales, which fell from $1.7 billion in Q3 2022 to $305 million in Q3 2023. Excluding these COVID-19 related sales, Abbott's total net sales actually increased by 12.6% on a reported basis and 14.1% excluding foreign exchange impacts, indicating robust underlying growth across its other business segments. The company's Medical Devices and Nutritional Products segments showed strong performance, with Medical Devices growing 16.6% and Nutritional Products up 15.5% year-over-year in the third quarter. The Established Pharmaceutical Products segment also saw a modest increase of 3.2%. However, the Diagnostic Products segment experienced a significant 32.7% decline, largely due to the aforementioned decrease in COVID-19 testing demand. For the first nine months of 2023, total net sales decreased 11.0% to $29.868 billion, also heavily influenced by the drop in COVID-19 testing revenue. Net earnings remained stable for the third quarter at $1.436 billion, compared to $1.435 billion in the prior year, with diluted earnings per share at $0.82.

Abbott Laboratories (ABT) filed an 8-K on October 17, 2023, to report its financial results for the third quarter of 2023, which were announced on October 18, 2023. The filing primarily incorporates a press release detailing these results. Investors should note that Abbott, as is common practice, utilizes both GAAP (Generally Accepted Accounting Principles) and non-GAAP financial measures. The non-GAAP measures adjust for items such as acquisition-related expenses, restructuring costs, voluntary recalls, impairment charges, and tax adjustments, which management believes offer better insight into ongoing operational performance. While these non-GAAP figures aim to provide a clearer view of the core business, it is crucial for investors to consider them alongside, and not as a substitute for, the standard GAAP measures. The press release, furnished as Exhibit 99.1, will contain the detailed financial performance data. Investors seeking specific performance metrics, including revenue, earnings, and segment-specific results, should refer to this accompanying press release, as the 8-K itself mainly serves as a notification of the earnings release.

This 8-K filing is an amendment to a previous report filed on May 2, 2023, concerning Abbott Laboratories' (ABT) Annual Meeting of Shareholders held on April 28, 2023. The primary purpose of this amendment is to correct a typographical error in the reported number of shares cast against Michael F. Roman, a key executive. The amendment clarifies the voting results for Mr. Roman, providing updated figures for votes cast for, against, abstentions, and broker non-votes. For investors, this filing is largely administrative and confirms the original outcome of the shareholder vote regarding Mr. Roman's re-election. While the correction itself is minor and does not alter the overall outcome of the shareholder vote, it demonstrates Abbott's commitment to accurate reporting. The overwhelming majority of votes were cast in favor of Mr. Roman, indicating continued shareholder confidence in leadership.

Abbott Laboratories reported a net sales decrease of 11.4% to $9.98 billion for the second quarter of 2023, largely driven by a significant decline in COVID-19 testing sales. Excluding COVID-19 testing and the impact of foreign exchange, total net sales grew by 11.9%. The Medical Devices segment showed robust growth, increasing 13.5% (15.4% excluding foreign exchange), bolstered by strong performance in Diabetes Care and contributions from recent acquisitions. The Diagnostic segment experienced a substantial decline of 46.0% (44.7% excluding foreign exchange), primarily due to lower demand for COVID-19 tests. Net earnings for the quarter decreased to $1.375 billion ($0.78 per diluted share) from $2.018 billion ($1.14 per diluted share) in the prior year. This decline reflects the reduced sales from COVID-19 diagnostics and increased operating costs, partly offset by the acquisition of Cardiovascular Systems, Inc. (CSI) and ongoing margin improvement initiatives. Despite the top-line contraction driven by the normalization of COVID-19 testing, Abbott's core businesses continue to demonstrate resilience and growth, particularly in its Medical Devices segment.

Abbott Laboratories (ABT) filed an 8-K on July 20, 2023, to report its second-quarter 2023 financial results. The report primarily furnished a press release detailing the company's performance. Investors should note that Abbott, like many companies, utilizes non-GAAP financial measures to present its results, adjusting for items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, impairment charges, and tax-related adjustments. Management believes these measures offer a clearer view of ongoing operational performance, supplementing the standard GAAP reporting.

Abbott Laboratories (ABT) has announced a significant leadership transition within its finance department, effective September 1, 2023. This 8-K filing details the appointments of key finance executives, including Robert E. Funck, Jr. as Executive Vice President, Finance. Philip P. Boudreau will step into the role of Senior Vice President, Finance and Chief Financial Officer, continuing to report to Mr. Funck. John A. McCoy, Jr. has been appointed Vice President, Controller. These appointments reflect a strategic alignment of financial leadership within Abbott. Mr. Boudreau's long tenure and extensive experience within the company, including his recent role as Vice President, Controller, position him well for his new CFO responsibilities. Mr. McCoy's background, including his recent role as Vice President, Treasurer, also provides a solid foundation for his new position as Controller. Investors should monitor how these leadership changes impact financial strategy and execution moving forward.

This 8-K/A filing from Abbott Laboratories serves as an amendment to their previous 8-K filing dated May 2, 2023, which reported on the outcomes of their Annual Meeting of Shareholders held on April 28, 2023. The key update relates to the compensation of named executive officers. Following the shareholder vote and in line with the Board of Directors' recommendation, Abbott has confirmed that an advisory vote on executive compensation will be conducted annually going forward. This decision means shareholders will have an ongoing opportunity to provide their non-binding input on the compensation packages of Abbott's top executives. While advisory in nature, these votes are closely watched by the Board and management and can influence future compensation decisions. Investors should note that this is a procedural update regarding the frequency of the "say-on-pay" vote, rather than a change in compensation policy itself.

Abbott Laboratories reported net sales of $9.75 billion for the first quarter of 2023, a decrease of 18.1% compared to the prior year's $11.9 billion. This decline was primarily driven by a significant drop in COVID-19 testing sales, which fell from $3.3 billion in Q1 2022 to $730 million in Q1 2023. Excluding COVID-19 testing sales and the impact of foreign exchange, Abbott's total net sales increased by 9.4%, indicating underlying strength in its other business segments. Despite the overall sales decline, Abbott's Medical Devices segment showed robust growth, increasing by 12.4% (excluding foreign exchange), fueled by strong performance in Diabetes Care (FreeStyle Libre sales up 25.4%), Structural Heart, and other cardiovascular areas. The Established Pharmaceutical Products and Nutritional Products segments also saw modest growth, while the Diagnostic Products segment experienced a substantial decrease largely due to the winding down of COVID-19 test demand. Diluted earnings per share were $0.75, down from $1.37 in the prior year, reflecting the impact of lower sales and other operational factors.

Abbott Laboratories (ABT) filed an 8-K on May 2, 2023, detailing the results of its Annual Meeting of Shareholders held on April 28, 2023. The report confirms the election of all nominated directors to the Board and the ratification of Ernst & Young LLP as the company's independent auditor. Shareholder approval was also given for the advisory vote on executive compensation and for holding this vote annually. Importantly, several shareholder proposals were voted down. These included proposals related to lowering the threshold for calling special meetings, requiring an independent board chairman, disclosing lobbying expenditures, and adjusting executive compensation metrics to exclude legal/compliance costs. The overwhelming support for the company's nominees and auditor, along with the rejection of these specific shareholder initiatives, signals continued confidence from the majority of shareholders in the current governance and operational strategies of Abbott Laboratories.

Abbott Laboratories (ABT) reported its first quarter 2023 financial results on April 19, 2023. The company provided a press release, furnished as Exhibit 99.1, detailing its performance. Notably, the report highlights Abbott's use of non-GAAP financial measures, which exclude items such as acquisition-related expenses, restructuring actions, voluntary recall costs, certain regulatory costs, and tax-related adjustments. Management believes these non-GAAP measures offer investors better insight into ongoing business performance by removing unusual or unpredictable factors, similar to internal assessments. While the specific financial figures are detailed in the press release (Exhibit 99.1), this 8-K filing primarily serves to announce the results and reference the accompanying press release. Investors are advised to consider these non-GAAP measures alongside traditional GAAP figures for a comprehensive understanding of Abbott's financial health and operational efficiency.

Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 28, 2023, the Board of Directors will be reduced from thirteen members to twelve persons. This change is administrative and does not appear to be tied to any immediate strategic shifts or financial performance indicators disclosed in this specific filing.

Abbott Laboratories reported strong performance in its 2022 fiscal year, driven by its diversified healthcare portfolio across Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutritional Products. The company demonstrated resilience despite various market challenges, including supply chain disruptions and the ongoing impact of the COVID-19 pandemic, though the latter led to a notable decline in COVID-19 testing revenues as anticipated. Key growth drivers included the Medical Devices segment, bolstered by its Diabetes Care products like FreeStyle Libre, and the Established Pharmaceuticals segment, which saw continued expansion in emerging markets. The company navigated the significant impact of a voluntary infant formula recall and subsequent manufacturing issues within its Nutritional Products segment, implementing strategies to mitigate supply shortages. Despite these challenges, Abbott maintained a strong financial position, evidenced by consistent dividend payouts and a significant share repurchase program. The company also announced a strategic acquisition in the medical device space, signaling continued investment in growth and innovation. Management expressed confidence in future growth driven by product development and market expansion across all segments.

Abbott Laboratories (ABT) has filed an 8-K report on January 25, 2023, to announce its fourth quarter and full year 2022 financial results. The filing primarily includes a press release containing these results. Investors should note that Abbott, like many companies, utilizes non-GAAP financial measures to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, voluntary recalls, certain litigation, and tax adjustments. While these non-GAAP measures aim to offer better insight into the core business performance as assessed by management, investors are reminded to consider these alongside the Generally Accepted Accounting Principles (GAAP) measures. The press release itself, furnished as an exhibit, contains the detailed financial performance data for the periods ending December 31, 2022. Investors seeking specific figures on revenue, earnings, and segment performance should refer to this press release.

Abbott Laboratories (ABT) filed an 8-K on December 9, 2022, to report the amendment and restatement of its by-laws, effective immediately. These changes primarily focus on updating and clarifying the procedural mechanics and information requirements for shareholder nominations of directors and shareholder proposals at meetings. This includes specific provisions related to Rule 14a-19 under the Exchange Act, which governs proxy access. The amendments also address special meetings, the powers of the Board and meeting Chair, and include other ministerial, conforming, and gender-neutrality updates. While these amendments are primarily procedural and do not alter Abbott's financial performance or strategic direction, they are important for shareholders to understand as they impact how shareholder actions can be brought forth and managed at company meetings. Investors should be aware that these changes are designed to ensure compliance with evolving regulations and to streamline meeting governance.

Abbott Laboratories reported net sales of $10.41 billion for the third quarter of 2022, a 4.7% decrease year-over-year, impacted by a 6.0% unfavorable foreign exchange impact. Excluding the impact of foreign exchange, total net sales saw a 1.3% increase, driven by growth in Medical Devices and Established Pharmaceuticals, though this was partially offset by a decline in Nutritional Products and COVID-19 testing-related revenues. For the first nine months of 2022, net sales increased by 6.2% to $33.56 billion, with a 10.9% increase excluding foreign exchange impacts. This growth was significantly boosted by a substantial increase in COVID-19 testing-related sales, alongside positive contributions from Medical Devices and Established Pharmaceuticals. Despite a dip in quarterly sales, the company's financial performance for the nine-month period shows resilience. Net earnings for the quarter decreased to $1.435 billion ($0.81 diluted EPS) from $2.10 billion ($1.17 diluted EPS) in the prior year, primarily due to factors including the voluntary product recall in the Nutritional segment and increased manufacturing and supply chain costs. However, nine-month net earnings rose to $5.90 billion ($3.32 diluted EPS) from $5.08 billion ($2.83 diluted EPS) in the prior year. The company continues to manage its capital through share repurchases and dividends, with $3.116 billion remaining under its current share repurchase program. The company also noted an impairment charge of $111 million on certain IPR&D intangible assets within the Medical Devices segment.

Abbott Laboratories (ABT) has filed an 8-K report on October 21, 2022, primarily addressing the extension of its Change in Control Agreements with its named executive officers. These agreements, originally set to expire on December 31, 2022, have been extended for an additional two years, now through December 31, 2024. This extension provides continuity and stability for key leadership during a period that could involve significant corporate events. For investors, this action signals Abbott's commitment to retaining its executive team and maintaining a stable leadership structure. The extension of these agreements suggests management's confidence in the company's future and its ongoing strategies. While the filing itself does not disclose specific financial performance or new business initiatives, it reassures stakeholders about leadership continuity, which is often a positive indicator for long-term strategic execution and stability.

Abbott Laboratories (ABT) filed an 8-K on October 19, 2022, to report its third-quarter 2022 financial results. The filing primarily consists of a press release detailing these results and is furnished as an exhibit. Investors should note that Abbott utilizes non-GAAP financial measures, which exclude certain items such as acquisition-related expenses, restructuring costs, voluntary recalls, litigation, and impairment charges, among others. The company states that these adjustments provide a clearer view of ongoing business performance, aligning with how management internally assesses results.

Abbott Laboratories (ABT) filed an 8-K on September 15, 2022, primarily announcing two key governance changes. The company appointed Claire Babineaux-Fontenot to its Board of Directors, effective September 15, 2022. This addition brings new expertise and perspectives to the board's oversight. In conjunction with this appointment, Abbott's Board of Directors also amended its bylaws to increase the size of the board from twelve to thirteen members. This adjustment provides the necessary capacity for the new director and allows for potential future expansion. Investors should view these as routine corporate governance actions aimed at strengthening the board's composition and effectiveness.

Abbott Laboratories reported strong top-line growth in the second quarter and first half of 2022, with total net sales increasing by 10.1% and 15.9% respectively, excluding the impact of foreign exchange. This growth was largely driven by a significant surge in demand for its COVID-19 diagnostic tests, particularly within the Rapid Diagnostics segment, which saw a 70.4% increase in sales (excluding FX) in the first half. Excluding COVID-19 testing sales, overall net sales still demonstrated resilience, growing by 4.1% in Q2 and 1.7% in the first half on an organic basis. The company experienced notable growth in its Medical Devices segment, particularly in Diabetes Care driven by the FreeStyle Libre continuous glucose monitoring system. However, the Nutritional Products segment faced headwinds, notably due to a voluntary infant formula recall in the U.S. impacting U.S. Pediatric Nutritionals sales significantly. Despite these challenges and a negative impact from foreign exchange due to a strong U.S. dollar, Abbott maintained healthy profitability with improved gross profit margins.

Abbott Laboratories (ABT) filed an 8-K on July 20, 2022, to announce its second quarter 2022 financial results. The filing primarily furnished a press release detailing these results. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, which exclude items such as acquisition-related expenses, restructuring costs, voluntary recall expenses, and certain litigation and tax items. The company asserts that these non-GAAP measures provide greater visibility into ongoing business performance and are used internally for performance assessment.

Abbott Laboratories reported strong first-quarter 2022 results, driven by significant growth in its Diagnostics segment, largely attributed to COVID-19 testing solutions. Total net sales increased by 13.8% to $11.9 billion, with an impressive 17.5% increase when excluding foreign exchange impacts. The company saw robust growth in its Medical Devices and Established Pharmaceutical Products segments, while the Nutritional Products segment experienced a decline primarily due to a voluntary recall of infant formula products and associated production stoppage in the U.S. Despite challenges, including the infant formula recall and unfavorable foreign exchange rates, Abbott demonstrated strong operational execution. Diluted earnings per share rose to $1.37 from $1.00 in the prior year period. The company's robust cash flow from operations and solid balance sheet provide a stable financial foundation for future investments and shareholder returns.

This 8-K filing from Abbott Laboratories details the outcomes of its Annual Meeting of Shareholders held on April 29, 2022. Key investor-focused information includes the overwhelming re-election of the entire Board of Directors and the ratification of Ernst & Young LLP as the company's auditor. Shareholders also approved the compensation of named executive officers in an advisory vote. The filing also outlines several shareholder proposals that were rejected by the majority of votes cast, including proposals related to special meeting thresholds, independent board chair, Rule 10b5-1 plans, lobbying expenditures, and antimicrobial resistance reporting. From an investor's perspective, the broad support for the board and auditor indicates a level of confidence in current management and governance. The rejection of most shareholder proposals suggests that the board's current strategies and policies are favored by the majority of shareholders, or at least that the proposals did not garner sufficient support to pass. The advisory vote on executive compensation passing with over 91% approval is a positive signal regarding shareholder alignment on pay practices.

Abbott Laboratories (ABT) filed an 8-K on April 20, 2022, to report its first quarter 2022 financial results. The filing primarily serves to furnish the press release detailing these results, which was issued on the same day. Investors should note that Abbott utilizes non-GAAP financial measures to provide additional insight into its operational performance. These measures adjust for specific items such as acquisition-related expenses, restructuring costs, voluntary recalls, and amortization of intangibles, aiming to offer a clearer view of ongoing business performance as assessed by management.

Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 29, 2022, the Board of Directors will be reduced from thirteen to twelve members. This change, approved by the Board of Directors on February 18, 2022, revises Article III, Section 2 of Abbott's bylaws. While this is a procedural change related to corporate governance, investors should note that such adjustments in board size can sometimes precede or accompany other strategic shifts, though no specific strategic implications are mentioned in this filing. The filing also includes updated bylaws and cover page interactive data. The report was signed by Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer.